Utah Medical Products, Inc.
Utah Medical Products, Inc. (UTMD) Financial Performance & Income Statement Overview
Review Utah Medical Products, Inc. (UTMD) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Utah Medical Products, Inc. (UTMD) Income Statement & Financial Overview
View the income breakdown for Utah Medical Products, Inc. UTMD across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $9.71M | $9.16M | $10.005M | $10.40M |
| Cost of Revenue | $4.17M | $3.83M | $4.20M | $4.66M |
| Gross Profit | $5.54M | $5.32M | $5.80M | $5.74M |
| Gross Profit Ratio | $0.57 | $0.58 | $0.58 | $0.55 |
| R&D Expenses | $155000.00 | $121000.00 | $172000.00 | $255000.00 |
| SG&A Expenses | $2.23M | $1.94M | $2.29M | $2.56M |
| Operating Expenses | $2.39M | $2.39M | $2.46M | $2.81M |
| Total Costs & Expenses | -$6.56M | $6.23M | $6.66M | $6.96M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | -$705000.00 | $730000.00 | $728000.00 | $693000.00 |
| EBITDA | $3.15M | $3.98M | $4.08M | $4.13M |
| EBITDA Ratio | $0.32 | $0.44 | $0.41 | $0.40 |
| Operating Income | $3.15M | $2.93M | $3.34M | $3.44M |
| Operating Income Ratio | $0.32 | $0.32 | $0.33 | $0.33 |
| Other Income/Expenses (Net) | $707000.00 | $684000.00 | $836000.00 | $773000.00 |
| Income Before Tax | $3.86M | $3.61M | $4.18M | $4.21M |
| Income Before Tax Ratio | $0.40 | $0.39 | $0.42 | $0.40 |
| Income Tax Expense | $818000.00 | $712000.00 | $616000.00 | $758000.00 |
| Net Income | $3.04M | $2.90M | $3.56M | $3.45M |
| Net Income Ratio | $0.31 | $0.32 | $0.36 | $0.33 |
| EPS | $0.92 | $0.86 | $1.02 | $0.95 |
| Diluted EPS | $0.92 | $0.86 | $1.02 | $0.98 |
| Weighted Avg Shares Outstanding | $3.31M | $3.39M | $3.48M | $3.62M |
| Weighted Avg Shares Outstanding (Diluted) | $3.31M | $3.39M | $3.48M | $3.53M |
Over the last four quarters, Utah Medical Products, Inc. achieved steady financial progress, growing revenue from $10.40M in Q2 2024 to $9.71M in Q1 2025. Gross profit stayed firm with margins at 57% in Q1 2025 versus 55% in Q2 2024. Operating income totaled $3.15M in Q1 2025, maintaining a 32% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $3.15M. Net income rose to $3.04M, with EPS at $0.92. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan